logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
R

Rachel M. Layman

university of texas
H指数:30
被引数:3,653

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy

III期postMONARCH试验中，阿贝西利联合氟维司群与安慰剂联合氟维司群治疗既往接受过CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌的总体生存率

Annals of Oncology
IF65.4
2026-10-240
OA
Kevin Kalinsky; Seth A. Wander; Erika Hamilton; Stephanie L. Graff; Rinath Jeselsohn; Kyong Hwa Park; Umut Demirci; Miguel Martin; Rachel M. Layman; Sara A. Hurvitz; Sarah Sammons; Peter A. Kaufman; Elizabeth Ravenberg; Sasha Amdur; Lacey M. Litchfield; Giampaolo Bianchini
Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience

BRCA生殖系突变携带者晚期乳腺癌接受PARP（聚腺苷二磷酸核糖聚合酶）抑制剂治疗的特征与临床结局：单机构经验

Cancers
IF4.4
2026-04-170
OA
Fatma Nihan Akkoc Mustafayev; Elena Fountzilas; Mark F. Munsell; Rachel M. Layman; Clinton Yam; Angelica M. Gutierrez; Constance T. Albarracin; Zamal Ahmed; Katharina Schlacher; John A. Tainer; Banu K. Arun
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/ 6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2-metastatic breast cancer in US routine clinical practice

美国常规临床实践中，HR+/HER2-转移性乳腺癌患者使用CDK4/6抑制剂联合芳香化酶抑制剂的真实世界无进展生存期2（PFS2）和肿瘤缓解情况

Breast
IF7.9
2026-04-010
OAAI
Rugo, Hope S.; Brufsky, Adam; Layman, Rachel M.; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B.; Estevez, Melissa; Lynce, Filipa; Cottu, Paul; Thill, Marc; Curigliano, Giuseppe
Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition

回顾性分析显示，激素受体阳性转移性炎性乳腺癌患者对细胞周期依赖性激酶4/6抑制剂的应答不佳。

Breast Cancer Research
IF5.6
2025-12-100
OAAI
Azadeh Nasrazadani; Rebecca S. Tidwell; Megumi Kai; Bora Lim; Vicente Valero; Debu Tripathy; Sadia Saleem; Bisrat G. Debeb; Anthony Lucci; Wendy A. Woodward; Rachel M. Layman
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

新辅助HER2靶向方案联合或未联合蒽环类药物用于HER2阳性炎性乳腺癌：一项多中心回顾性研究

Breast Cancer Research and Treatment
IF3
2025-08-020
PRE
Toshiaki Iwase; Nithya Sridhar; Megumi Kai; Wenli Dong; Yu Shen; Savitri Krishnamurthy; Anthony Lucci; H. T. Carisa Le-Petross; Azadeh Nasrazadani; Sadia Saleem; Rachel M. Layman; Vincente Valero; Debasish Tripathy; Wendy A. Woodward; Yee Chung Cheng; Faina Nakhlis; Jenifer R. Bellon; Filipa Lynce; Naoto T. Ueno
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

激素受体阳性、HER2阴性晚期乳腺癌患者在接受gedatolisib联合palbociclib和内分泌治疗（一项评估gedatolisib的1b期临床试验）治疗后的总生存期

lancet oncology
IF0
2025-06-300
PRE
Rachel M Layman; Hyo S Han; Hope S Rugo; Erica M Stringer-Reasor; Jennifer M Specht; E Claire Dees; Peter Kabos; Samuel Suzuki; Sarah C Mutka; Brian F Sullivan; Igor Gorbatchevsky; Robert Wesolowski
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

MEK抑制剂曲美替尼单独或与AKT抑制剂GSK2141795/乌普罗替尼联合治疗转移性三阴性乳腺癌患者的II期研究

BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-12-071
PRE
Prasath, Vishnu; Boutrid, Hinda; Wesolowski, Robert; Abdel-Rasoul, Mahmoud; Timmers, Cynthia; Lustberg, Maryam; Layman, Rachel M.; Macrae, Erin; Mrozek, Ewa; Shapiro, Charles; Glover, Kristyn; Vater, Mark; Budd, G. Thomas; Harris, Lyndsay; Isaacs, Claudine; Dees, Claire; Perou, Charles M.; Johnson, Gary L.; Poklepovic, Andrew; Chen, Helen; Villalona-Calero, Miguel; Carson, William; Stover, Daniel G.; Ramaswamy, Bhuvaneswari
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study

转移性三阴性炎性乳腺癌患者的免疫检查点抑制剂 (integrle): 一项国际队列研究

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
PRE
Valenza, Carmine; Trapani, Dario; Zagami, Paola; Antonarelli, Gabriele; Bielo, Luca Boscolo; Nicolo, Eleonora; Ribeiro, Joana Mourato; Guidi, Lorenzo; Reduzzi, Carolina; Spotti, Martina; Adamoli, Laura; Cortes, Javier; Pistilli, Barbara; Tolaney, Sara M.; Ueno, Naoto; Layman, Rachel M.; Cristofanilli, Massimo; Carey, Lisa A.; Munzone, Elisabetta; Criscitiello, Carmen; Lynce, Filipa; Woodward, Wendy A.; Curigliano, Giuseppe
Abemaciclib plus fulvestrant for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial

Abemaciclib联合fulvestrant用于既往接受过CDK4/6抑制剂联合内分泌治疗进展后的HR+、HER2-晚期乳腺癌：postMONARCH III期试验的亚组分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Bianchini, G.; Jimenez, M. Martin; Graff, S.; Jeselsohn, R.; Wander, S.; Layman, R.; Hurvitz, S. A.; Hamilton, E. P.; Sammons, S.; Kaufman, P.; Knoderer, H.; Nguyen, B.; Zhou, Y.; Ravenberg, E.; Litchfield, L.; Kalinsky, K.

研究方向

暂未获取到该数据
A
Adam Brufsky
H 指数:94论文数:1,004被引数:3.6万
W
Wendy A. Woodward
H 指数:78论文数:891被引数:2.0万
L
Lynn McRoy
H 指数:16论文数:111被引数:995
B
Benjamin Li
H 指数:27论文数:266被引数:2,687
D
Debu Tripathy
H 指数:69论文数:1,158被引数:2.5万
X
Xianchen Liu
H 指数:19论文数:78被引数:1,259
H
Hope S. Rugo
H 指数:137论文数:1,617被引数:10.1万
N
Naoto T. Ueno
H 指数:97论文数:1,425被引数:4.8万
E
Ewa Mrózek
H 指数:25论文数:108被引数:2,481
V
Vicente Valero
H 指数:118论文数:967被引数:4.8万